|Eltanexor, also known as KPT-8602, is a second-generation exportin-1 (CRM1) inhibitor with IC50 values of 20−211 nM in 10 AML lines.
|KPT-330 is a first-in-class, oral, selective inhibitor of Nuclear Export (SINE) compound, works by binding to and inhibiting the nuclear export protein XPO1 (also known as CRM1).
|Felezonexor (CBS9106; SL-801) is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity without affecting CRM1 mRNA levels. Felezonexor is also a reversible inhibitor of XPO1, inhibits nuclear export by covalently binding to Cys528 as well as by inducing the degradation of XPO1.
|Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.
|KPT-276 is an orally bioavailable selective CRM1 inhibitor.
|KPT-185 is a selective CRM1 inhibitor.
|CRM1-IN-2 is a noncovalent CRM1 inhibitor.
|CRM1-IN-1 is a noncovalent CRM1 inhibitor.
|KPT-251 is an orally active chromosome region maintenance 1 protein (CRM1) inhibitor. KPT-251 induces cancer cell apoptosis and shows antileukemic activity.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.